Celldex Therapeutics (NASDAQ:CLDX) Price Target Cut to $50.00 by Analysts at Barclays

Celldex Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Barclays cut its Celldex price target from $53 to $50 but maintained an “overweight” rating; the new target implies about 79.75% upside from the share price cited in the report.
  • Analyst sentiment is broadly positive: Celldex has a “Moderate Buy” consensus and an average price target of $63.33, with 11 Buy, one Hold, and one Sell rating.
  • Celldex reported quarterly earnings of a $0.96 loss per share, beating estimates of a $1.02 loss, while revenue of $0.40 million came in below the $0.72 million estimate.
  • Interested in Celldex Therapeutics? Here are five stocks we like better.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) had its target price cut by stock analysts at Barclays from $53.00 to $50.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an "overweight" rating on the biopharmaceutical company's stock. Barclays's target price suggests a potential upside of 79.75% from the stock's current price.

Several other equities research analysts have also weighed in on the company. Wells Fargo & Company raised their target price on Celldex Therapeutics from $48.00 to $72.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Leerink Partners boosted their target price on Celldex Therapeutics from $70.00 to $88.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 23rd. HC Wainwright lowered their price target on Celldex Therapeutics from $64.00 to $58.00 and set a "buy" rating for the company in a report on Friday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Celldex Therapeutics in a research note on Thursday, October 15th. Finally, Stifel Nicolaus set a $68.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, September 22nd. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Celldex Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $63.33.

View Our Latest Report on Celldex Therapeutics

Celldex Therapeutics Trading Down 0.5%

Shares of CLDX stock opened at $27.82 on Friday. The company has a market cap of $2.19 billion, a P/E ratio of -6.40 and a beta of 1.04. The firm has a fifty day moving average price of $31.11 and a 200 day moving average price of $32.83. Celldex Therapeutics has a 12 month low of $22.33 and a 12 month high of $45.14.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, beating analysts' consensus estimates of ($1.02) by $0.06. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.72 million. On average, equities analysts forecast that Celldex Therapeutics will post -4.12 EPS for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

Several large investors have recently bought and sold shares of CLDX. Wellington Management Group LLP increased its position in shares of Celldex Therapeutics by 11.5% during the second quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company's stock worth $355,120,000 after purchasing an additional 983,195 shares in the last quarter. Commodore Capital LP lifted its holdings in shares of Celldex Therapeutics by 5.1% in the 1st quarter. Commodore Capital LP now owns 2,696,616 shares of the biopharmaceutical company's stock valued at $85,537,000 after purchasing an additional 131,616 shares during the last quarter. Baker BROS. Advisors LP boosted its position in shares of Celldex Therapeutics by 116.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 2,564,984 shares of the biopharmaceutical company's stock valued at $83,131,000 after purchasing an additional 1,382,373 shares during the period. Eversept Partners LP boosted its position in shares of Celldex Therapeutics by 24.6% in the 1st quarter. Eversept Partners LP now owns 1,788,016 shares of the biopharmaceutical company's stock valued at $56,716,000 after purchasing an additional 353,291 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of Celldex Therapeutics by 26.5% in the 3rd quarter. Fisher Asset Management LLC now owns 1,246,855 shares of the biopharmaceutical company's stock valued at $40,411,000 after purchasing an additional 261,178 shares during the period.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells. The company's lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity. Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.

See Also

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Celldex Therapeutics Right Now?

Before you consider Celldex Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.

While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines